Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.

Clinical advances in hematology & oncology : H&O - 1 Oct 2011

Erba Harry P, Pham Dat C, Zaiden Robert, Vu Ho, Tai Shawn

Abstract excerpt

The approval of imatinib in 2001 changed the landscape of chronic myeloid leukemia (CML) management, becoming the standard of care and improving the survival rates of patients. With the prevalent use of imatinib worldwide, it was observed that up to one-third of patients are resistant to or intolerant of imatinib therapy, fueling the search for safer and more effective agents. The newer and more potent tyrosine...

Topics

Join the communities discussing this publication.

Benzamides
Dasatinib
Fusion Proteins, bcr-abl
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 22252576

Genes

ABL1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.PMID 22252576Read ↗

Optimizing second-line therapy for chronic myeloid leukemia.Semantic proximity Read ↗

Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.Semantic proximity Read ↗

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.Semantic proximity Read ↗

Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia.Semantic proximity Read ↗

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.Semantic proximity Read ↗

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.Semantic proximity Read ↗

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.Semantic proximity Read ↗

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.Semantic proximity Read ↗

Therapy options in imatinib failures.Semantic proximity Read ↗

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.Semantic proximity Read ↗

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.Semantic proximity Read ↗

Tyrosine kinase inhibitors: the first decade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.